보고서 정보
주관연구기관 |
(주)네오팜 |
보고서유형 | 최종보고서 |
발행국가 | 대한민국 |
언어 |
한국어
|
발행년월 | 2015-12 |
과제시작연도 |
2014 |
주관부처 |
보건복지부 [Ministry of Health & Welfare(MW)(MW) |
등록번호 |
TRKO201600004514 |
과제고유번호 |
1465016646 |
사업명 |
글로벌화장품신소재.신기술연구개발지원 |
DB 구축일자 |
2016-08-20
|
키워드 |
카나비노이드 수용체.아토피 피부염.건선.보습제.지루성 피부염.Cannabinoid receptor.atopic dermatitis.psoriasis.moisturizer.seborrheic dermatitis.
|
DOI |
https://doi.org/10.23000/TRKO201600004514 |
초록
▼
- 피부 내 카나비노이드 수용체의 활성을 조절하는 물질을 발굴함.
- 다양한 피부 질환에서 카나비노이드 수용체의 발현 및 활성 변화를 관찰하여, 사업화 대상 질환 및 물질을 확정함.
- 카나비노이드 수용체 1 (CB1R)에 대한 활성화 효과를 지닌 신규 화장품 원료를 발굴하고, 세포 실험과 다양한 피부질환 동물모델을 이용하여 개발 원료의 효능을 평가함.
- 개발 물질을 화장품 원료로 등재하고, 시제품 개발을 완료함.
- 시제품의 임상 효능을 아토피 피부염, 건선, 지루성 피부염 환자를 대상으로 확인함.
-
- 피부 내 카나비노이드 수용체의 활성을 조절하는 물질을 발굴함.
- 다양한 피부 질환에서 카나비노이드 수용체의 발현 및 활성 변화를 관찰하여, 사업화 대상 질환 및 물질을 확정함.
- 카나비노이드 수용체 1 (CB1R)에 대한 활성화 효과를 지닌 신규 화장품 원료를 발굴하고, 세포 실험과 다양한 피부질환 동물모델을 이용하여 개발 원료의 효능을 평가함.
- 개발 물질을 화장품 원료로 등재하고, 시제품 개발을 완료함.
- 시제품의 임상 효능을 아토피 피부염, 건선, 지루성 피부염 환자를 대상으로 확인함.
- 지루성 피부염 개선 효과를 지닌 최종 제품을 출시 완료함.
Abstract
▼
1. Objectives
Due to the continuous changes in social conditions, increased number of aged population, and environmental pollutions, the incidence and prevalence of chronic inflammatory skin diseases, such as atopic dermatitis and psoriasis, has been steadily increased. Identification of new pote
1. Objectives
Due to the continuous changes in social conditions, increased number of aged population, and environmental pollutions, the incidence and prevalence of chronic inflammatory skin diseases, such as atopic dermatitis and psoriasis, has been steadily increased. Identification of new potential targets for improving inflammatory symptoms can not only widen the understanding of the disease's pathophysiology, but also offer new area for produce development. The objectives of this R&D program are to investigate the roles of cannabinoid receptors (CBR) in skin (patho)physiology and to develope new cosmetic ingredients with CBR activity modulating effects.
2. Materials and Methods
The screening system for CBR activity measurement was established by transfecting CB1R or CB2R expressing vectors into CHO cells. New small molecules were synthesized, based on their structural similarity to the endocannabinoids, and their CBR activity modulating effects were measured. Also, expressions of CBRs in normal and diseases skin were observed by immunohictochemical staining. Using an in vitro and in vivo models, the activities of screened CB1R activators were investigated. Lastly, clinical efficacies of topical moisturizer formulation containing the newly developed CB1R activator were assessed in atopic dermatitis, psoriasis, and seborrheic dermatitis.
3. Results
With the established CBR activating assay system, effects of newly synthesizied compounds were screened. As a result, agonist and antagonist of CB1R and CB2R were identified. Based on the decreased expression of CB1R in inflammatory skin lesions, CB1R activators were further developed as new cosmetic ingredients. The therapeutic effects of selected compounds were evaluated by in vitro and in vivo models, including oxazolone-induced atopic dermatitis model and imiquimod-induced psoriasis model. Topical moisturizer formulations containing newly developed ingredients were prepared and clinical efficacy of those formulations were assessed in atopic dermatitis, atopic dermatitis, and seborrheic dermatitis, respectively. Most significant improvements in symptoms were observed in seborrheic dermatitis patients.Finished product, named as Zeroid Pimprove SD Care gel, were launched in the market.
4. Conclusion
Newly developed CB1R activator, Restomide, showed anti-inflammatory activity in various in vitro and in vivo models, as well as clinical efficacy tests.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.